KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medpace Holdings (MEDP) Net Income (2016 - 2025)

Historic Net Income for Medpace Holdings (MEDP) over the last 11 years, with Q4 2025 value amounting to $135.1 million.

  • Medpace Holdings' Net Income rose 1548.05% to $135.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $451.1 million, marking a year-over-year increase of 1155.75%. This contributed to the annual value of $451.1 million for FY2025, which is 1155.75% up from last year.
  • Latest data reveals that Medpace Holdings reported Net Income of $135.1 million as of Q4 2025, which was up 1548.05% from $111.1 million recorded in Q3 2025.
  • In the past 5 years, Medpace Holdings' Net Income registered a high of $135.1 million during Q4 2025, and its lowest value of $39.9 million during Q2 2021.
  • In the last 5 years, Medpace Holdings' Net Income had a median value of $71.7 million in 2023 and averaged $78.3 million.
  • The largest annual percentage gain for Medpace Holdings' Net Income in the last 5 years was 6567.37% (2021), contrasted with its biggest fall of 163.57% (2021).
  • Over the past 5 years, Medpace Holdings' Net Income (Quarter) stood at $50.0 million in 2021, then soared by 37.25% to $68.7 million in 2022, then increased by 14.02% to $78.3 million in 2023, then skyrocketed by 49.45% to $117.0 million in 2024, then rose by 15.48% to $135.1 million in 2025.
  • Its Net Income was $135.1 million in Q4 2025, compared to $111.1 million in Q3 2025 and $90.3 million in Q2 2025.